New to Medtech Insight?
Start a free trial today!
Register for our free email digests:
Register for our free email digests:
Brenda Sandburg
New York, NY
Brenda Sandburg is a senior writer who covers legal issues and FDA regulatory policy, with a particular focus on patents, biosimilars, and government investigations. She spent 10 years writing for legal publications between stints at The Pink Sheet and blends these experiences to provide in-depth analysis of events. An aspiring photographer, she enjoys taking photos to accompany news stories.
Advertisement
Remove Alert
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Brenda Sandburg
Walgreens Agrees To Oversight, Settles Insulin Pen Overdispensing, Discount Pricing Claims
DOJ settlements totaling $269m resolve two False Claims Act cases; company enters corporate integrity agreement requiring independent review organization to assess claims.
Sale of Invention May Block Its Patenting Even If Details Are Not Disclosed, Supreme Court Concludes
America Invents Act did not alter the meaning of "on sale," unanimous court finds, so a confidential sale can qualify as prior art.
Medicare Part D Payment Model Gives Health Plans More Incentives To Negotiate Lower Drug Prices
Participating plans to share in savings if they stay below spending target for Part D catastrophic phase and repay 10% of any excess spending; CMS also updates its VBID model.
US Federal Courts Can Operate Until Jan. 25; Patent Office Faces Eminent Closure Under Shutdown
Federal courts and USPTO will soon run out of funds that have allowed them to continue normal operations; pending ANDAs to get same filing date, which could lead to FDA legal challenges.
Bristol-Celgene: Congressional Reps Want Assurance Merger Will Not Increase Prices
Reps. Welch and Rooney urge FTC and DOJ to condition their approval of the merger on inclusion of a pricing provision.
Co-Pay Vouchers May Not Be Enough To Boost Patient Adherence To Blood Thinners
Acute MI patients who received voucher had 3.3% increase in persistence with clopidogrel or ticagrelor, but no significant reduction in major adverse cardiovascular events, ARTEMIS study finds.
Advertisement